Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Advanced/Metastatic Colorectal Cancer
Interventions
DRUG

LTC004+regorafenib

LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06322563 - Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC | Biotech Hunter | Biotech Hunter